Schemitsch, Emil
Adachi, Jonathan D.
Brown, Jacques P.
Tarride, Jean-Eric
Burke, Natasha
Oliveira, Thiago
Slatkovska, Lubomira http://orcid.org/0000-0001-5027-7989
Funding for this research was provided by:
Amgen Canada
Article History
Received: 21 January 2021
Accepted: 20 July 2021
First Online: 11 August 2021
Declarations
:
: ES has received consulting fees from Acumed LLC, Amgen, Implants for Trauma Surgery, Pentopharm, Sanofi-Aventis, Smith & Nephew, Stryker, Swemac; received grant/research support from Amgen, Biocomposites, Smith & Nephew. JDA has received consulting fees from Amgen; received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Pfizer, Radius. JPB has received consulting fees and honoraria from Amgen and Servier; received research funding from Mereo BioPharma, Radius Health, Servier; served on speakers’ bureau for Amgen. JET has received consulting fees from Amgen, Analytica Laser International, AstraZeneca, Bayer, Edwards Lifesciences, Eli Lilly, The European Commission Initiative on Breast Cancer, Evidera, Flatiron, GSK, Merck, Novartis, PCDI Canada, Pfizer, Roche; received grant/research support from Amgen, Assurex/Myriad, AstraZeneca, CSL Behring, Edwards Lifesciences, Novo Nordisk, Sage; served on speakers’ bureau for Allergan. TO, NB and LS are employees and own stock in Amgen.
: The study protocol was approved by the Advarra Institutional Review Board.
: Formal consent is not required for this type of study.
: Not applicable.